Robert W Frenck

List of Publications by Year
in descending order

50 papers	19,534 citations	257450 24 h-index	243625 44 g-index
53 all docs	53 docs citations	53 times ranked	27192 citing authors

#	Article	IF	Citations
1	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 2020, 383, 2603-2615.	27.0	11,472
2	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 2020, 383, 2439-2450.	27.0	2,107
3	PhaseÂI/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 2020, 586, 589-593.	27.8	1,197
4	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine, 2021, 385, 1761-1773.	27.0	1,090
5	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. New England Journal of Medicine, 2021, 385, 239-250.	27.0	709
6	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine, 2022, 386, 35-46.	27.0	431
7	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. New England Journal of Medicine, 2021, 385, 1627-1629.	27.0	346
8	Patients with Inflammatory Bowel Disease Are at Risk for Vaccine-Preventable Illnesses. American Journal of Gastroenterology, 2006, 101, 1834-1840.	0.4	304
9	Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults. Journal of Infectious Diseases, 2015, 211, 870-878.	4.0	223
10	Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2010, 105, 148-154.	0.4	171
11	Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccineâ€“naÃ¯ve adults 60â€“64 years of age. Vaccine, 2014, 32, 2364-2374.	3.8	136
12	Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine, 2013, 31, 3594-3602.	3.8	132
13	Predicting Susceptibility to Norovirus GII.4 by Use of a Challenge Model Involving Humans. Journal of Infectious Diseases, 2012, 206, 1386-1393.	4.0	124
14	Serological Correlates of Protection against a GII.4 Norovirus. Vaccine Journal, 2015, 22, 923-929.	3.1	109
15	Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?. Clinical Infectious Diseases, 2021, 73, 336-340.	5.8	70
16	Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults. Vaccine Journal, 2012, 19, 1296-1303.	3.1	64
17	Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (FluzoneÂ®) administered by intradermal and intramuscular route in healthy adults. Vaccine, 2011, 29, 5666-5674.	3.8	63
18	Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged â‰¥18 Years. Clinical Infectious Diseases, 2022, 75, 390-398.	5.8	60

#	Article	IF	Citations
19	Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. Lancet Infectious Diseases, The, 2019, 19, 631-640.	9.1	53
20	Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. Vaccine, 2017, 35, 375-384.	3.8	52
21	Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial. Vaccine, 2017, 35, 385-394.	3.8	43
22	Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. EClinicalMedicine, 2021, 39, 101076.	7.1	37
23	Development of Pathogenicityâ€Driven Definitions of Outcomes for a Field Trial of a Killed Oral Vaccine against EnterotoxigenicEscherichia coliin Egypt: Application of an Evidenceâ€Based Method. Journal of Infectious Diseases, 2004, 189, 2299-2307.	4.0	32
24	Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2011, 30, 1086-1091.	2.0	32
25	A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei. Vaccine, 2018, 36, 4880-4889.	3.8	30
26	13-valent Pneumococcal Conjugate Vaccine in Older Children and Adolescents Either Previously Immunized With or NaÃ¯ve to 7-valent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2014, 33, 183-189.	2.0	25
27	Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G. MSphere, 2020, 5, .	2.9	25
28	Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies. Clinical Infectious Diseases, 2019, 69, S580-S590.	5.8	24
29	Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints. Clinical Infectious Diseases, 2019, 69, S591-S595.	5.8	23
30	Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine, 2016, 34, 3454-3462.	3.8	22
31	The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. Expert Opinion on Biological Therapy, 2012, 12, 63-77.	3.1	20
32	Developing and utilizing controlled human models of infection. Vaccine, 2017, 35, 6813-6818.	3.8	20
33	Immunogenicity, Safety and Tolerability of 3 Lots of 13-valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations in the United States. Pediatric Infectious Disease Journal, 2013, 32, 871-880.	2.0	19
34	Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G. MSphere, 2020, 5, .	2.9	13
35	Shigella -Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei. MSphere, 2021, 6, e0012221.	2.9	12
36	Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag). Open Forum Infectious Diseases, 2020, 7, ofz532.	0.9	10

#	Article	IF	Citations
37	Melody Valve Bartonella henselae Endocarditis in an Afebrile Teen: A Case Report. Pediatrics, 2016, 137, .	2.1	9
38	Pharmacokinetics and pharmacogenomics of Î²-lactam-induced neutropenia. Pharmacogenomics, 2016, 17, 547-559.	1.3	7
39	Varicella vaccine safety and immunogenicity in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care and Research, 2010, 62, 903-906.	3.4	4
40	Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding. PLoS ONE, 2021, 16, e0259361.	2.5	4
41	Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. Vaccine, 2017, 35, 3564-3574.	3.8	2
42	Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. Pediatric Infectious Disease Journal, 2021, 40, e234-e235.	2.0	2
43	A cross-sectional household cluster serosurvey of hepatitis C virus antibodies in an urban slum of Cairo, Egypt in 2004. Tropical Diseases, Travel Medicine and Vaccines, 2015, 1, 9.	2.2	1
44	Shigella-Controlled Human Infection Models: Current and Future Perspectives. Current Topics in Microbiology and Immunology, 2021, , .	1.1	1
45	599Rapid rises in antibody titers observed following single dose administration of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) to healthy adults. Open Forum Infectious Diseases, 2014, 1, S25-S25.	0.9	0
46	1098The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions. Open Forum Infectious Diseases, 2014, 1, S324-S324.	0.9	0
47	1102Immunogenicity and Safety of a Second Administration of 13-Valent Pneumococcal Conjugate Vaccine Five Years after Initial Vaccination in Adults 50 Years and Older. Open Forum Infectious Diseases, 2014, 1, S325-S326.	0.9	0
48	The Dynamics of Staphylococcus aureus carriage and Comparisons by Age in Two Studies of an Investigational S aureus 4-Antigen Vaccine (SA4Ag). Open Forum Infectious Diseases, 2016, 3, .	0.9	0
49	Response to Letter to the Editor regarding: Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18â€“49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. Vaccine, 2016, 34, 4467.	3.8	0
50	A site assessment tool for inpatient controlled human infection models for enteric disease pathogens. Clinical Trials, 2022, 19, 116-118.	1.6	0